Literature DB >> 10593935

Perlecan mediates the antiproliferative effect of apolipoprotein E on smooth muscle cells. An underlying mechanism for the modulation of smooth muscle cell growth?

L Paka1, I J Goldberg, J C Obunike, S Y Choi, U Saxena, I D Goldberg, S Pillarisetti.   

Abstract

Apolipoprotein E (apoE) is known to inhibit cell proliferation; however, the mechanism of this inhibition is not clear. We recently showed that apoE stimulates endothelial production of heparan sulfate (HS) enriched in heparin-like sequences. Because heparin and HS are potent inhibitors of smooth muscle cell (SMC) proliferation, in this study we determined apoE effects on SMC HS production and cell growth. In confluent SMCs, apoE (10 microg/ml) increased (35)SO(4) incorporation into PG in media by 25-30%. The increase in the medium was exclusively due to an increase in HSPGs (2.2-fold), and apoE did not alter chondroitin and dermatan sulfate proteoglycans. In proliferating SMCs, apoE inhibited [(3)H]thymidine incorporation into DNA by 50%; however, despite decreasing cell number, apoE increased the ratio of (35)SO(4) to [(3)H]thymidine from 2 to 3.6, suggesting increased HS per cell. Purified HSPGs from apoE-stimulated cells inhibited cell proliferation in the absence of apoE. ApoE did not inhibit proliferation of endothelial cells, which are resistant to heparin inhibition. Analysis of the conditioned medium from apoE-stimulated cells revealed that the HSPG increase was in perlecan and that apoE also stimulated perlecan mRNA expression by >2-fold. The ability of apoE isoforms to inhibit cell proliferation correlated with their ability to stimulate perlecan expression. An anti-perlecan antibody completely abrogated the antiproliferative effect of apoE. Thus, these data show that perlecan is a potent inhibitor of SMC proliferation and is required to mediate the antiproliferative effect of apoE. Because other growth modulators also regulate perlecan expression, this may be a key pathway in the regulation of SMC growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593935     DOI: 10.1074/jbc.274.51.36403

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Apolipoprotein E-induced cell signaling in the vessel wall.

Authors:  David Y Hui
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

Review 2.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

3.  Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222.

Authors:  Devashish Kothapalli; Paola Castagnino; Daniel J Rader; Michael C Phillips; Sissel Lund-Katz; Richard K Assoian
Journal:  Atherosclerosis       Date:  2012-12-19       Impact factor: 5.162

4.  Role of apolipoprotein E in renal damage protection.

Authors:  F Bonomini; L F Rodella; M Moghadasian; C Lonati; R Coleman; R Rezzani
Journal:  Histochem Cell Biol       Date:  2011-05-15       Impact factor: 4.304

Review 5.  Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain.

Authors:  Marcos A Marques; Phillip A Owens; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease.

Authors:  Marcos A Marques; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

7.  Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation.

Authors:  Devashish Kothapalli; Ilia Fuki; Kamilah Ali; Sheryl A Stewart; Liang Zhao; Ron Yahil; David Kwiatkowski; Elizabeth A Hawthorne; Garret A FitzGerald; Michael C Phillips; Sissel Lund-Katz; Ellen Puré; Daniel J Rader; Richard K Assoian
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

8.  Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling.

Authors:  Heather A Walker; John M Whitelock; Pamela J Garl; Raphael A Nemenoff; Kurt R Stenmark; Mary C M Weiser-Evans
Journal:  Mol Biol Cell       Date:  2003-01-26       Impact factor: 4.138

9.  Vascular apolipoprotein e expression and recruitment from circulation to modulate smooth muscle cell response to endothelial denudation.

Authors:  Zachary W Q Moore; Binghua Zhu; David G Kuhel; David Y Hui
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

10.  Distinct effects of glucose and glucosamine on vascular endothelial and smooth muscle cells: evidence for a protective role for glucosamine in atherosclerosis.

Authors:  Wenlan Duan; Latha Paka; Sivaram Pillarisetti
Journal:  Cardiovasc Diabetol       Date:  2005-10-05       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.